Home
About
FAQ
History (1)
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W, Ghamrawi R, Haidari W, Feldman SR. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. Ann Pharmacother. 2020 04; 54(4):380-387.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Biological Products
Humans
Interleukin-23 Subunit p19
Psoriasis
Severity of Illness Index
Treatment Outcome
United States
United States Food and Drug Administration
authors with profiles
Steven R. Feldman MD, PhD